Compare LGIH & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | SVRA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | 2009 |
| Metric | LGIH | SVRA |
|---|---|---|
| Price | $58.80 | $5.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $75.90 | $7.33 |
| AVG Volume (30 Days) | 300.8K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | $430.87 |
| P/E Ratio | $45.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.55 | $2.92 |
| 52 Week High | $69.42 | $7.01 |
| Indicator | LGIH | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 49.07 |
| Support Level | $55.45 | $5.28 |
| Resistance Level | $62.97 | $6.09 |
| Average True Range (ATR) | 2.77 | 0.26 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 68.60 | 44.71 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).